• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Fonar Corporation

    9/12/25 4:31:45 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $FONR alert in real time by email
    NT 10-K 1 fonar_12b-25.htm FORM 12B-25 NOTIFICATION OF LATE FILING FOR PERIOD ENDED: JUNE 30, 2025

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    SEC FILE NUMBER 0-10248

    CUSIP NUMBER 344437-10-8

     

    (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K

    [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR

     

    For Period Ended: June 30, 2025

     

    [ ] Transition Report on Form 10-K

    [ ] Transition Report on Form 20-F

    [ ] Transition Report on Form 11-K

    [ ] Transition Report on Form 10-Q

    [ ] Transition Report on Form N-SAR

     

    For the Transition Period Ended: _________________

     

     

    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

    ________________________________________________________________

     

    Part I - REGISTRANT INFORMATION

     

      FONAR CORPORATION  
      Full Name of Registrant  
         
      RAANEX II CORPORATION  
      Former Name if Applicable  
         
      110 MARCUS DRIVE  
     

    Address of Principal Executive Office

    (Street and Number)

     
         
      MELVILLE, NY 11747  
      City, State and Zip Code  

     

     
     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

    [X](b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III – NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report of portion thereof, could not be filed within the prescribed time period.

     

    The Company has experienced unexpected delays and is unable to file its Annual Report on Form 10-K by the prescribed due date without unreasonable effort or expense. We expect to file within 15 calendar days of the prescribed due date.

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    JOHN P. COLLINS   (631)   694-2929
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    [X] Yes [ ] No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    [ ]Yes [X] No

     

     If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     
     

     

      FONAR CORPORATION  
      (Name of Registrant as Specified in Charter)  

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 12, 2025

    By /s/ TIMOTHY R. DAMADIAN,

    Timothy R. Damadian, President and CEO

     

     

    Get the next $FONR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FONR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FONR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fonar Announces Financial Results For The 1st Quarter of Fiscal 2026

    Cash and cash equivalents decreased 4% to $54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 4% to $26.0 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $3.2 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Consolidated Net Income decreased 33% to $2.7 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Diluted Net Income per Common Share decreased 26% to $0.34 for the quarter ended September 30, 2025 versus the corresponding quarter one

    11/10/25 8:00:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    FONAR Announces Financial Results for Fiscal 2025

    Cash and Cash Equivalents was $56.3 million at June 30, 2025 and the previous fiscal year. Total Revenues - Net increased 1% to $104.4 million for the fiscal year ended June 30, 2025 versus the previous fiscal year.Income from Operations decreased 30% to $11.6 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Net Income decreased 24% to $10.7 million for the fiscal year ended June 30, 2025 versus the previous fiscal year.Diluted Net Income per Common Share decreased 20% to $1.23 for the fiscal year ended June 30, 2025 versus the previous fiscal year.Working Capital increased by 4% to $127.5 million for the fiscal year ended June 30, 2025 versus the previous fis

    9/12/25 8:27:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Special Committee of FONAR Board of Directors Announces Receipt of Supplemental "Take Private" Proposal

    Melville, New York--(Newsfile Corp. - July 18, 2025) - The Special Committee of the Board of Directors of FONAR Corporation (NASDAQ:FONR) ("FONAR"), The Inventor of MR Scanning™, today confirmed receipt of a supplemental proposal letter, dated July 17, 2025, from the Proposed Acquisition Group led by Timothy Damadian. The supplemental letter states that the Proposed Acquisition Group is contemplating the pursuit of a plan to acquire all of the outstanding shares capital stock of FONAR not currently owned by the Proposed Acquisition Group, at a price of $17.25 per share in cash. The letter states that the proposed share price represents a premium of approximately 27% over the average closin

    7/18/25 4:15:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

    4 - FONAR CORP (0000355019) (Issuer)

    10/3/22 6:41:44 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Damadian Timothy Raymond bought $65,205 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $13.87), increasing direct ownership by 12% to 42,700 units

    4 - FONAR CORP (0000355019) (Issuer)

    10/3/22 6:16:39 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    SEC Filings

    View All

    Fonar Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - FONAR CORP (0000355019) (Filer)

    11/12/25 2:05:19 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Fonar Corporation

    10-Q - FONAR CORP (0000355019) (Filer)

    11/10/25 12:56:59 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Fonar Corporation

    10-K - FONAR CORP (0000355019) (Filer)

    9/22/25 4:45:18 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Financials

    Live finance-specific insights

    View All

    Fonar Announces Financial Results For The 1st Quarter of Fiscal 2026

    Cash and cash equivalents decreased 4% to $54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 4% to $26.0 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $3.2 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Consolidated Net Income decreased 33% to $2.7 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Diluted Net Income per Common Share decreased 26% to $0.34 for the quarter ended September 30, 2025 versus the corresponding quarter one

    11/10/25 8:00:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    FONAR Announces Financial Results for Fiscal 2025

    Cash and Cash Equivalents was $56.3 million at June 30, 2025 and the previous fiscal year. Total Revenues - Net increased 1% to $104.4 million for the fiscal year ended June 30, 2025 versus the previous fiscal year.Income from Operations decreased 30% to $11.6 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Net Income decreased 24% to $10.7 million for the fiscal year ended June 30, 2025 versus the previous fiscal year.Diluted Net Income per Common Share decreased 20% to $1.23 for the fiscal year ended June 30, 2025 versus the previous fiscal year.Working Capital increased by 4% to $127.5 million for the fiscal year ended June 30, 2025 versus the previous fis

    9/12/25 8:27:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

    Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

    11/12/24 7:00:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Leadership Updates

    Live Leadership Updates

    View All

    FONAR Board of Directors Appoints Independent Director

    Melville, New York--(Newsfile Corp. - July 2, 2025) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the Company's board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position. The Company is very grateful for Ms. Chan's years of service and loyalty to FONAR.Timothy Damadian, chairman and CEO of FONAR, said, "Our primary source of income and growth is attributable to our diagnostic imaging management subsidiary, Health Management Company of America (HMCA). In 2009, HMCA managed 9

    7/2/25 4:10:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    FONAR Board of Directors Appoints Independent Director

    Melville, New York--(Newsfile Corp. - March 20, 2023) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that its board of directors appointed Jessica Maher as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, chairman, president and CEO of FONAR, said, "FONAR's primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). As a management company, HMCA bills and collects for all services rendered at HMCA-managed and HMCA-owned facilities. These facilities, all of them located in New York and Florida and coll

    3/20/23 11:37:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fonar Board of Directors Appoints Independent Director

    Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered

    11/23/21 2:07:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fonar Corporation

    SC 13G - FONAR CORP (0000355019) (Subject)

    11/14/24 12:27:58 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Fonar Corporation

    SC 13G - FONAR CORP (0000355019) (Subject)

    2/13/24 5:04:39 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

    SC 13G/A - FONAR CORP (0000355019) (Subject)

    2/13/24 4:05:17 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care